What does real-world data reveal about cangrelor's safety? An analysis of FDA adverse event reporting system (FAERS)...

Area of Science:

• Pharmacovigilance
• Cardiovascular Medicine
• Drug Safety

Background:

• Limited real-world safety data exists for cangrelor, a drug used to prevent thrombotic events during percutaneous coronary intervention.
• This study addresses the need for comprehensive safety information by analyzing adverse events associated with cangrelor.

Purpose of the Study:

• To analyze adverse events (AEs) related to cangrelor using the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) database.
• To identify both expected and unexpected safety concerns associated with cangrelor use.

Main Methods:

• Utilized the FAERS database, encompassing over 15 million case reports.
• Employed advanced statistical methods including reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker.

Main Results:

• Identified 209 cangrelor-related events, with 31 distinct adverse events across eight organ systems.
• Off-label use (163 events) was the most frequently reported preferred term, with significant associations with acute myocardial infarction and antiplatelet/anticoagulant therapies.
• Discovered unexpected adverse events not listed in current drug labeling, such as cardiac arrest and cardiac failure.

Conclusions:

• Cangrelor's safety profile includes both anticipated and unexpected adverse events.
• Identified issues related to product application, emphasizing the need for manufacturers to clarify indications and usage.
• Recommended strict adherence to drug administration protocols by healthcare professionals to mitigate risks.